The estimated Net Worth of Raymond Pawlicki is at least $2.67 Миллион dollars as of 22 November 2013. Raymond Pawlicki owns over 4,000 units of Biogen Inc stock worth over $2,530,434 and over the last 12 years Raymond sold BIIB stock worth over $135,049.
Raymond has made over 7 trades of the Biogen Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Raymond exercised 4,000 units of BIIB stock worth $199,800 on 22 November 2013.
The largest trade Raymond's ever made was exercising 10,000 units of Biogen Inc stock on 6 February 2013 worth over $496,500. On average, Raymond trades about 3,054 units every 49 days since 2012. As of 22 November 2013 Raymond still owns at least 12,710 units of Biogen Inc stock.
You can see the complete history of Raymond Pawlicki stock trades at the bottom of the page.
Raymond's mailing address filed with the SEC is BIOGEN IDEC INC., 133 BOSTON POST RD., WESTON, MA, 02493.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner и Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: